NEW YORK (GenomeWeb News) – Nextcode Health officially launched today, saying it has licensed technology developed by Decode Genetics that it will use to accelerate the diagnosis of cancer through sequencing-based data.

The Cambridge, Mass.-based company also said that it has secured $15 million in Series A financing. Investors in the round included Polaris Partners and Arch Venture Partners, and the financing will be used to scale up the integration of its genomics services into clinical settings.

A Nextcode spokesperson confirmed the company is a spinout of Decode.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.